Have a personal or library account? Click to login
A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality Cover

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

Acta Pharmaceutica
Volume 74 (2024): Issue 1 (March 2024)
By: Nem Kumar Jain,  Mukul Tailang,  Neelaveni Thangavel,  Hafiz A. Makeen,  Mohammed Albratty,  Asim Najmi,  Hassan Ahmad Alhazmi,  Khalid Zoghebi,  Muthumanickam Alagusundaram,  Hemant Kumar Jain and  Balakumar Chandrasekaran  
Open Access
|Mar 2024
DOI: https://doi.org/10.2478/acph-2024-0005 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 1 - 36
Accepted on: Nov 9, 2023
Published on: Mar 30, 2024
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
FGFR,
tyrosine kinase inhibitors,
FDA approval,
erdafitinib,
infigratinib,
pemigatinib,
futibatinib
Related subjects:
Pharmacy,
Pharmacy, other

© 2024 Nem Kumar Jain, Mukul Tailang, Neelaveni Thangavel, Hafiz A. Makeen, Mohammed Albratty, Asim Najmi, Hassan Ahmad Alhazmi, Khalid Zoghebi, Muthumanickam Alagusundaram, Hemant Kumar Jain, Balakumar Chandrasekaran, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 74 (2024): Issue 1 (March 2024)Next article